Assurance Infusion Recalls BUP 20MG/SUF 105MCG/ML Injection Due to Sterility Concerns
Assurance Infusion is recalling BUP 20MG/SUF 105MCG/ML Injection in 20 mL syringes due to a lack of sterility assurance. The recall is nationwide.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score under the rubric for significant injury or property damage reports or high-risk contamination.
Plain-English summary
Assurance Infusion is recalling BUP 20MG/SUF 105MCG/ML Injection in 20 mL syringes. The recall is being conducted because of a lack of sterility assurance in the product.
The affected product is identified by Lot 12122019@8 with an expiration date of 12/21/2019. The recall is distributed nationwide within the United States.
Consumers and healthcare providers should stop using the affected product and contact Assurance Infusion at (713) 533-8800 for further instructions.
The recalled product
- Product
- BUP 20MG/SUF 105MCG/ML INJ in 20 mL syringe Assurance Infusion (713) 533-8800
- Manufacturer
- Assurance Infusion
- Category
- Drug — Injection
- Hazard
- Affected units
- 1
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: 12122019@8 Exp. 12/21/2019
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 118 recalled by Assurance Infusion under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 118 products in this recall →Related recalls
Same manufacturer · Assurance Infusion
See all →- SevereAssurance Infusion Recalls Buprenorphine and Hydromorphone Injection Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SevereAssurance Infusion Recalls Hydromorphone Injection Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SevereAssurance Infusion Recalls Fentanyl Syringes Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SevereAssurance Infusion Recalls Morphine Injection Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SevereAssurance Infusion Recalls Buprenorphine and Morphine Injection Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
Same hazard · sterility
See all →- HighFDA recalls injectable compounded mixture in single-use syringes
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereInfusion Options Recalls Mitomycin Syringes Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
- HighInfusion Options Recalls Azacitidine Syringes Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
- HighMIC/B12 Injectable Vials Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2022-09-21
- SevereAtezolizumab Infusion Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2019-08-21
- SevereIron Sucrose Infusion Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2019-08-21
- SevereInfliximab Infusion Bags Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2019-08-21